Medication info
Ritamezin Sustained Release Tablet 2.5/1000 mg (Linagliptin (Unmodified), Metformin Hydrochloride)

Ritamezin Sustained Release Tablet 2.5/1000 mg (Linagliptin (Unmodified), Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Linagliptin Micronized›2.5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Kyungdong Pharmaceutical Co., Ltd.
Appearance
Yellow oval-shaped sustained-release film-coated tablet
Packaging
Bottle - 30 tablets/bottle, Bottle - 100 tablets/bottle
Approval status
Active

MFDS item code 202400185 · Approved 2024.01.24 · Insurance code 648105000

Summary

Main use
Improves blood glucose control in type 2 diabetes
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: linagliptin 5mg and metformin hydrochloride (extended-release) 2000 mg. This medicine should be taken once daily with a meal, preferably with the evening meal. Take one tablet of this medicine 5/1000 mg extended-release tablet once daily. Patients taking this medicine 2.5/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin treatment: The initial dose of this medicine is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin treatment - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this medicine consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this medicine is administered in combination with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine should be the patient's current doses of linagliptin and extended-release metformin hydrochloride. No dose adjustment of this medicine is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), defined as creatinine clearance (CrCl) ≥ 45mL/min and < 60mL/min or estimated glomerular filtration rate (eGFR) ≥ 45mL/min/1.73m2 and < 60mL/min/1.73m2, this medicine may be used with metformin hydrochloride dose adjustment as follows, provided it is well tolerated and there are no other conditions that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this medicine should be discontinued immediately.

Ingredients

Manufacturer
Kyungdong Pharmaceutical Co., Ltd.

Efficacy & effects

Improves blood glucose control in type 2 diabetes

View approved original text

This medication is used to help patients with type 2 diabetes control their blood sugar when taking Linagliptin and Metformin together. When taken along with diet and exercise therapy, it helps to effectively manage blood sugar levels. This can facilitate better diabetes management and help prevent complications. It is a medication that greatly aids in maintaining healthy blood sugar levels for patients.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: linagliptin 5mg and metformin hydrochloride (extended-release) 2000 mg. This medicine should be taken once daily with a meal, preferably with the evening meal. Take one tablet of this medicine 5/1000 mg extended-release tablet once daily. Patients taking this medicine 2.5/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin treatment: The initial dose of this medicine is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin treatment - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this medicine consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this medicine is administered in combination with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine should be the patient's current doses of linagliptin and extended-release metformin hydrochloride. No dose adjustment of this medicine is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), defined as creatinine clearance (CrCl) ≥ 45mL/min and < 60mL/min or estimated glomerular filtration rate (eGFR) ≥ 45mL/min/1.73m2 and < 60mL/min/1.73m2, this medicine may be used with metformin hydrochloride dose adjustment as follows, provided it is well tolerated and there are no other conditions that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this medicine should be discontinued immediately.

Precautions

This medication can rarely cause severe lactic acidosis or hypoglycemia, so if these symptoms occur, immediate medical consultation should be sought. Do not use this medication if you have allergies to any of its components, or if you have type 1 diabetes, lactic acidosis, diabetic ketoacidosis, severe renal impairment, acute myocardial infarction, or certain diseases. Patients with decreased kidney function should have their kidney function tested before administering this medication and should be monitored regularly for kidney function. When used in combination with sulfonylureas or insulin, the risk of hypoglycemia may increase, so blood sugar levels should be closely monitored. In the case of acute illness or before and after surgery, the use of this medication should be temporarily discontinued and can be resumed after kidney function has returned to normal. This medication may cause gastrointestinal upset, abdominal pain, diarrhea, nausea, etc., so it is advisable to take it during or after meals. If acute pancreatitis or symptoms suggestive of a bullous skin disease occur during taking the medication, stop immediately and consult with a healthcare professional. Long-term use may lead to vitamin B12 deficiency, so if symptoms of anemia or neurological symptoms occur, vitamin B12 levels should be checked. It is recommended to avoid using this medication during pregnancy or breastfeeding, and to consult a doctor if planning a pregnancy. This medication may interact with other drugs, so inform your healthcare provider about any other medications being taken. Elderly patients may have a potential decrease in kidney function, so dose adjustments and regular kidney function tests are necessary. This medication should not be chewed or crushed, and should be swallowed whole; the tablet coating may pass in the stool, which is normal. Keep out of reach of children and store away from moisture.

Side effects

Lactic acidosis, hypoglycemia, nasopharyngitis, hypersensitivity reaction, angioedema, urticaria, abnormal vitamin B12 absorption test, taste disturbance, cough, loss of appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcer, abnormal liver function test, hepatitis, pruritus, erythema, rash, pemphigoid-like lesions, joint pain accompanied by severe symptoms and disabilities, rhabdomyolysis, increased lipase, increased amylase, upper abdominal pain, enterocolitis, intestinal obstruction, gastroenteritis, shingles, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, stuttering, Alzheimer-type dementia, chest pain, fever, facial edema, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot disease, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, stomach cancer, rectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina pectoris, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, hearing loss, dizziness, anxiety, mood disorder, insomnia, depression, contusion, bone contusion, concussion, bone fracture, hand fracture, chest discomfort, weakness, pain, nosebleed, oropharyngeal pain, voice disorder, allergic rhinitis, exercise-induced dyspnea, wet cough, runny nose, lung mass, joint pain, osteoporosis, arthropathy, musculoskeletal discomfort, myositis, myalgia, soft tissue mass, postmenopausal osteoporosis, rotator cuff syndrome, male pattern baldness, hyperhidrosis, dermatitis, dry eye, glaucoma, cataract, ocular discomfort, allergic conjunctivitis, benign prostatic hyperplasia, confusion state, nocturia, dermatitis, hypertension, goiter, vitreous hemorrhage, erectile dysfunction, myelodysplastic syndrome, ligament sprain, flanks pain, vocal cord polyp, stomatitis, mediastinitis, rhinitis, fever, ligament sprain

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. It is best to maintain a storage temperature between 1°C and 30°C at room temperature. This will help preserve the medication's effectiveness and safety.

Appearance and packaging

Appearance

Yellow oval-shaped sustained-release film-coated tablet

Package unit

Bottle - 30 tablets/bottle, Bottle - 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.